- 1 Integrative proteogenomic analyses provide novel interpretations of type 1 diabetes risk loci
- 2 through circulating proteins
- 3 Tianyuan Lu^{1,*}, Despoina Manousaki^{2,3,4}, Lei Sun^{1,5}, and Andrew D. Paterson^{5,6,7,*}
- 4
- ¹Department of Statistical Sciences, Faculty of Arts and Science, University of Toronto, Toronto,
- 6 ON, Canada
- ²Department of Pediatrics, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada
- ³Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Université de
 Montréal, Montreal, QC, Canada
- ⁴Research Center of the Sainte-Justine University Hospital, Université de Montréal, Montreal,
- 11 QC, Canada
- ⁵ Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON,
- 13 Canada
- ⁶Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto,
- 15 ON, Canada
- ⁷Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada
- 17
- 18 ^{*}Correspondence to:
- 19 TianyuanLu(tianyuan.lu@mail.mcgill.ca)andAndrewD.Paterson20(andrew.paterson@sickkids.ca)
- 21 Address: Program in Genetics & Genomic Biology, The Hospital for Sick Children Research
- 22 Institute, PGCRL Rm 12.9835, 686 Bay Street, Toronto, ON M5G 0A4, Canada
- 23 24

25 Abstract (150 words)

26 Type 1 diabetes (T1D) requires new preventive measures and interventions. Circulating proteins 27 are promising biomarkers and drug targets. Leveraging genome-wide association studies (GWASs) of T1D (18,942 cases and 501,638 controls) and circulating protein abundances 28 29 (10,708 individuals), the associations between 1,565 circulating proteins and T1D risk were 30 assessed through Mendelian randomization, followed by multiple sensitivity and colocalization 31 analyses, examinations of horizontal pleiotropy, and replications. Genetically increased circulating abundances of CTSH, IL27RA, SIRPG, and PGM1 were associated with an increased 32 33 risk of T1D, consistently replicated in other cohorts. Bulk tissue and single-cell gene expression 34 profiles revealed strong enrichment of CTSH, IL27RA, and SIRPG in immune system-related 35 tissues, and PGM1 in muscle and liver tissues. Among immune cells, CTSH was enriched in B 36 cells and myeloid cells, while SIRPG was enriched in T cells and natural killer cells. These 37 proteins warrant exploration as T1D biomarkers or drug targets in relevant tissues.

40 Introduction

Type 1 diabetes is an autoimmune disease characterized by the destruction of pancreatic β 41 cells ¹⁻⁶, which are responsible for producing insulin. Although traditionally considered a disease 42 of children and adolescents, type 1 diabetes can be diagnosed at any age and can affect a 43 significant proportion of the global population $^{3-5}$. Despite continuing efforts to develop risk 44 predictors ⁷⁻⁹, few effective preventive measures for type 1 diabetes have been implemented in 45 public health practice. Following diagnosis, preserving residual β cell function and delaying type 46 1 diabetes-associated autoimmunity present challenges due to the multifactorial and 47 heterogeneous nature of the disease $3^{-5, 10}$. Consequently, there is an urgent need for new 48 biomarkers and drug targets for type 1 diabetes. 49

50

Circulating molecules participate in various biological processes and play essential roles 51 encompassing immune responses, signaling cascades, and regulatory mechanisms ¹¹⁻¹⁴. These 52 molecules may be promising biomarkers or drug targets because their abundances are 53 54 measurable and possibly modifiable. Autoantibodies to insulin, glutamic acid decarboxylase, islet antigen-2, zinc transporter 8, and other circulating proteins have emerged as markers for 55 characterizing type 1 diabetes ^{10, 15, 16}. Yet, establishing the causal roles of novel proteins is 56 difficult. The feasibility of conducting randomized controlled trials for these proteins remains 57 58 limited. Meanwhile, observational studies can encounter several pitfalls, including uncontrolled 59 confounding factors as well as reverse causation.

60

Mendelian randomization (MR) is an instrumental variable framework that can effectively 61 mitigate biases arising from confounding and reverse causation ^{17, 18}. MR employs genetic 62 63 variants as instruments for a risk factor (i.e. a circulating protein), and evaluates the potential causal effect of the risk factor on a disease outcome. MR relies on three core instrumental 64 variable assumptions ^{17, 18}. First, a genetic instrument should strongly predict the risk factor, 65 known as the relevance assumption. Second, the genetic instrument should not be associated 66 67 with confounders of the risk factor-disease outcome relationship, known as the independence assumption. Third, the genetic instrument should not act on the disease outcome through 68 69 alternative pathways other than the instrumented risk factor, known as the no horizontal 70 pleiotropy assumption. Recent large-scale proteo-genomic studies have identified ideal genetic 71 instruments for circulating protein abundances, which are lead variants in cis-protein quantitative trait loci (cis-pQTLs)¹¹⁻¹³. These genetic variants are unlikely to be associated with 72 73 confounders that influence the risk factor-disease outcome association, because of the 74 randomization at conception. Moreover, their proximity to protein-coding genes suggests a 75 direct influence on protein abundances, thereby reducing the risk of horizontal pleiotropy. Previous studies have implemented MR to investigate potential causal effects of circulating 76 protein abundances on the risks of several complex diseases ¹⁹⁻²². 77

78

While cis-pQTL-facilitated MR can pinpoint target proteins, it is important to note that circulating proteins originate from various sources ¹¹⁻¹³. These include but are not limited to endocrine cell secretion, cellular turnover and apoptosis, immune and inflammatory response,

82 and diet and nutrition. To further understand the underpinning disease mechanisms and open

83 new avenues for diagnostic and therapeutic advancements, it is crucial to identify candidate 84 tissues and cell types where the target proteins are primarily produced.

85

In this study, we conducted integrative proteogenomic analyses to systematically identify 86 87 potential biomarkers and drug targets for type 1 diabetes. We first capitalized on genetic 88 associations from large-scale genome-wide association studies (GWASs) to conduct MR, in 89 order to assess the associations between circulating protein abundances and type 1 diabetes 90 risk. We then prioritized target proteins through multiple sensitivity and colocalization analyses, 91 examinations of horizontal pleiotropy, and replications. Furthermore, we identified candidate 92 tissues and cell types through enrichment analyses, utilizing both bulk tissue and single-cell 93 gene expression profiles. Our findings underscore circulating proteins that exhibit a potential 94 causal effect on the risk of type 1 diabetes.

95

96 Results

97 Target protein prioritization through Mendelian randomization

98 An overview of this study is presented in **Figure 1**. After identification of cis-genetic instruments 99 and data harmonization, associations between circulating abundances of 1,565 proteins and 100 type 1 diabetes risk were assessed using MR. MR analyses of 135 (8.6%) proteins utilized LD 101 proxies of cis-genetic instruments (**Methods**). Details of genetic instruments are provided in

- 102 **Supplementary Table S1**.
- 103

A total of 12 associations between circulating protein abundances and type 1 diabetes risk reached the Bonferroni-corrected significance threshold (p-value < 3.2×10^{-5} ; Figure 2 and **Supplementary Figure S1**), excluding proteins whose coding genes map to the MHC region. These significant associations had a minimal F-statistic of 46.6, indicating a low risk of weak instrument bias. Full summary statistics of MR analyses are provided in **Supplementary Table S2**.

110

Of these 12 proteins, circulating abundances of CTSH, ANXA2, and CCL25 were instrumented using three cis-genetic instruments. Results of sensitivity analyses using weighted median, penalized weighted median, weighted mode, and MR-Egger methods were highly consistent with those obtained using the inverse variance weighted method (**Supplementary Table S3**). MR-Egger intercepts largely overlapped with the null, suggesting a low risk of directional horizontal pleiotropy (**Supplementary Table S3**).

117

118 Colocalization evidence, horizontal pleiotropy assessment, and replication

119 Colocalization analyses and horizontal pleiotropy assessment were performed to verify MR 120 assumptions for these 12 proteins (**Methods**). Strong (PP.H4 > 80%) or suggestive (PP.H4 > 50%) 121 evidence of colocalization between circulating protein abundance and type 1 diabetes risk was 122 observed for CTSH, RHOC, IL27RA, ANXA2, SIRPG, CCL25, and PGM1. Conversely, colocalization 123 evidence was limited for EBI3-IL27 complex, IL15RA, ERBB3, WARS, and ALDH2 (**Figures 2** and **3**, 124 **Supplementary Figure S2**, and **Supplementary Table S4**).

Among these target proteins supported by colocalization evidence, the genetic instruments of 126 127 both RHOC and ANXA2 were predicted to have stronger functional connections to neighboring 128 genes (i.e. *ICE2* and *ST7L*, respectively) other than their respective coding genes, as indicated by 129 V2G scores (Methods and Supplementary Table S5). In addition, the genetic instruments of 130 RHOC, ANXA2, SIRPG, and CCL25 have been associated with the expression or splicing of other neighboring genes, which introduces an elevated risk of horizontal pleiotropy. In contrast, the 131 genetic instruments of CTSH, IL27RA, and PGM1 demonstrated the strongest functional 132 133 connection to their respective coding genes, were not associated with the expression, splicing, 134 or translation of other neighboring genes, and had not been associated with other known risk 135 factors of type 1 diabetes in the Open Target database, thereby mitigating the risk of horizontal 136 pleiotropy (Figures 2 and Supplementary Tables S5 and S6).

137

138 Seven significant associations supported by colocalization evidence were re-evaluated when cisgenetic instruments could be identified in the deCODE study or the UKB-PPP study, or when the 139 associations could be assessed based on the type 1 diabetes GWAS meta-analysis by Robertson 140 141 et al (Methods, Figure 2, and Supplementary Table S7). Six of the seven associations were replicated using these additional resources with a consistent effect direction and a similar 142 magnitude of effect as obtained in the primary analyses (Supplementary Table S8). However, 143 based on the cis-genetic instrument identified in the UKB-PPP study, a one standard deviation 144 145 increase in genetically predicted circulating abundance of CCL25 was not associated with the risk of type 1 diabetes (odds ratio, OR = 1.01; 95% CI: 0.96-1.05; p-value = 0.82; Supplementary 146 Table S8). 147

148

149 Following these assessments, we prioritized CTSH, IL27RA, SIRPG, and PGM1 as target proteins 150 (Figures 2 and 3), while cautioning a moderate risk of horizontal pleiotropy affecting the genetic instrument of circulating SIRPG abundance. Specifically, genetically predicted circulating 151 abundances of CTSH, IL27RA, SIRPG, and PGM1 were associated with increased odds of 152 developing type 1 diabetes, with ORs of 1.17 (CTSH; 95%: 1.10-1.24; p-value = 9.3×10^{-7} ; PP.H4 = 153 99.6%), 1.13 (IL27RA; 95%: 1.07-1.19; p-value = 2.3x10⁻⁵; PP.H4 = 92.7%), 1.37 (SIRPG; 95%: 154 1.26-1.49; p-value = 4.3x10⁻¹³; PP.H4 = 86.6%), and 1.66 (PGM1; 95%: 1.40-1.96; p-value = 155 3.9x10⁻⁹; PP.H4 = 71.3%) per one standard deviation increase, respectively. 156

157

158 *Tissue and immune cell type enrichment of gene expression*

159 For each of the target protein-coding genes, enrichment of gene expression in 54 tissue sites 160 profiled by the GTEx Consortium was assessed to identify potential candidate tissues (Methods 161 and Supplementary Table S9). As a result, the expression of CTSH, IL27RA, and SIRPG was enriched in the whole blood with a tissue-specific enrichment z-score > 10 (Figure 4). 162 Furthermore, CTSH expression was enriched in Epstein-Barr virus-transformed lymphocytes and 163 164 SIRPG expression was enriched in the spleen, while IL27RA expression was enriched in both of 165 these tissues (Figure 4). In contrast, the expression of *PGM1* exhibited enrichment in skeletal 166 muscle, heart (left ventricle), and liver (Figure 4).

167

168 Whole blood-specific cis-eQTL of *CTSH* and liver-specific cis-eQTL of *PGM1* demonstrated strong 169 evidence of colocalization with the genetic associations with type 1 diabetes risk, while tissue-

specific cis-eQTLs of *IL27RA* and *SIRPG* did not show evidence of colocalization (Supplementary 170 171 Figure S3 and Supplementary Table S10). Importantly, the cis-genetic instruments of circulating 172 abundances of IL27RA and SIRPG were not strongly associated with their mRNA abundances in these candidate tissues (Supplementary Figure S4). Meanwhile, there was strong evidence of 173 174 colocalization between genetic associations with multiple isoforms of CTSH and SIRPG in whole 175 blood and the genetic associations with the risk of type 1 diabetes (Supplementary Table S11). 176 These cis-sQTLs also overlapped with cis-pQTLs of CTSH and SIRPG (**Supplementary Figure S5**), 177 respectively.

178

Given the enrichment of CTSH, IL27RA, and SIRPG expression in immune system-related tissues, 179 180 we further examined cell type-specific gene expression based on single-cell transcriptomic profiling of 329,762 immune cells, consisting of 45 curated cell types (**Methods** and **Figure 5A**). 181 182 Among these immune cells, it was evident that CTSH expression was enriched in B cells, excluding pro-B cells and pre-B cells, as well as in myeloid cells (Figure 5B, Supplementary 183 Figures 6A, Supplementary Figures 7-9, and Supplementary Table S12). On the other hand, 184 185 CTSH expression was depleted in T cells, albeit with modest expression observed in effector 186 memory CD4⁺ T cells (Teffector/EM CD4) and tissue-resident memory T-helper 1 and T-helper 17 cells (Trm Th1/Th17). Meanwhile, the expression level of IL27RA was moderate and 187 relatively consistent across most cell types (Figure 5C, Supplementary Figures 6B, 188 Supplementary Figures 7-9, and Supplementary Table S12). In contrast, SIRPG expression was 189 enriched in T cells and natural killer cells, and depleted in B cells and myeloid cells (Figure 5D, 190 Supplementary Figures 6C, Supplementary Figures 7-9, and Supplementary Table S12). 191

192

193 Mendelian disorders and incident disease outcomes associated with target proteins

Among the four target proteins, PGM1 was implicated in congenital disorder of glycosylation type 1t (CDG1T), an autosomal recessive disorder caused by PGM1 deficiency due to pathogenic homozygous or compound heterozygous mutations affecting the *PGM1* gene (OMIM#614921, **Supplementary Table S13**). The other target proteins did not have known implications in Mendelian disorders.

199

200 In the UK Biobank, observational associations between circulating protein abundances and 201 incident disease outcomes were only available for CTSH. Over 16 years of follow-up, a one 202 standard deviation increase in circulating CTSH abundance was associated with a 1.14-fold increased hazard of mortality (95% CI: 1.10-1.17; p-value = 1.7x10⁻¹⁷), and interestingly, a 1.16-203 204 fold increased hazard of type 2 diabetes based on physician-made diagnosis (95% CI: 1.11-1.21; p-value = 4.0x10⁻¹²; Supplementary Figure S10 and Supplementary Table S14). In addition, a 205 one standard deviation increase in circulating CTSH abundance was associated with elevated 206 207 risks of systemic lupus erythematosus (hazard ratio, HR = 1.37; 95% CI: 1.17-1.60; p-value = 1.1×10^{-4}), rheumatoid arthritis (HR = 1.18; 95% CI: 1.09-1.27; p-value = 2.7x10⁻⁵), and chronic 208 obstructive pulmonary disease (HR = 1.09; 95% CI: 1.05-1.14; p-value = 6.3×10^{-5} ; 209 210 Supplementary Figure S10 and Supplementary Table S14).

- 211
- 212 Discussion

213 Type 1 diabetes impacts millions of individuals worldwide, causing acute and chronic complications that profoundly deteriorate the quality of life and increase mortality rates ¹⁻⁶. 214 Managing type 1 diabetes typically requires insulin injections for glycemic control, resulting in a 215 significant socioeconomic burden^{23, 24}. There is an urgent need for innovative strategies to 216 prevent, intervene early, and manage the disease. In this study, we conducted MR-guided 217 218 target discovery to systematically examine circulating proteins that may play a crucial role in 219 the etiology of type 1 diabetes. We also identified candidate tissues and cell types enriched of 220 target protein-coding gene expression. Our study presents a curated selection of candidate 221 proteins with the potential as biomarkers or drug targets.

222

223 Our integrative proteogenomic analyses prioritized four target proteins, CTSH, IL27RA, SIRPG, 224 and PGM1. Increased circulating abundances of these proteins were predicted to increase the 225 risk of type 1 diabetes. Specifically, CTSH (cathepsin H) is a lysosomal cysteine protease involved in the degradation of lysosomal proteins $^{25, 26}$. CTSH in pancreatic islets may affect β cell 226 survival and insulin secretion by modulating apoptotic signaling pathways and transcription 227 factors ^{27, 28}. The genomic locus within the CTSH gene has previously been associated with the 228 risk of type 1 diabetes^{29, 30}. In this study, we observed that *CTSH* expression was enriched in B 229 230 cells and myeloid cells, implying a potential role of CTSH in antigen presentation and antibodymediated immunity. Furthermore, although the genetic risk may be conferred by gene 231 232 expression, which may be mediated by DNA methylation ³¹, colocalization between the genetic associations with multiple isoforms of CTSH in the whole blood and the risk of type 1 diabetes 233 234 suggests that alternative splicing of CTSH may contribute to the disease pathogenesis. In the UK 235 Biobank, increased circulating CTSH abundance was linked to higher mortality and risks of 236 common autoimmune diseases. Importantly, while the observational association analyses did 237 not encompass type 1 diabetes as an outcome due to the limited number of cases, increased 238 circulating CTSH abundance was associated with an increased risk of type 2 diabetes, defined 239 based on physician-made diagnosis. This suggests the possibility of misdiagnosing type 1 diabetes as type 2 diabetes ^{3, 32, 33} within the adult population of the UK Biobank. Increased 240 CTSH expression has also been associated with early-onset type 1 diabetes and rapid decline of 241 β cell function in other cohort studies ^{27, 34, 35}. Taken together, our findings strongly encourage 242 functional follow-up studies to explicate the role of CTSH in type 1 diabetes and to evaluate its 243 244 potential as a biomarker or drug target.

245

246 IL27RA (alpha subunit of the interleukin 27 receptor) binds to IL27, a heterodimeric cytokine composed of IL27p28 and EBI3 subunits ^{36, 37}. IL27 has both pro-inflammatory functions by 247 mediating T-helper 1 cell differentiation and increasing interferon γ production ³⁶⁻³⁸, and anti-248 inflammatory functions by inhibiting pro-inflammatory cytokines in T cells and promoting the 249 production of anti-inflammatory cytokines ³⁹⁻⁴¹. However, due to the lack of colocalization 250 evidence and potential horizontal pleiotropic effects, we were unable to determine the effect 251 252 of IL27. On the other hand, the association between circulating abundance of IL27RA and the 253 risk of type 1 diabetes was substantiated by multiple lines of evidence. The results of our enrichment analyses align with the involvement of IL27RA in cell-mediated and antibody-254 mediated immunity by mediating IL27 signaling in various immune cells ³⁶. While the functions 255 256 of IL27RA and IL27RA-mediated IL27 signaling in type 1 diabetes remain to be explored, we

257 posit that IL27 and IL27RA may regulate both innate and adaptive immune responses that 258 attack the pancreatic β cells.

259

260 SIRPG (signal-regulatory protein γ) is a receptor protein involved in the negative regulation of receptor tyrosine kinase-coupled signaling processes ⁴². It has been suggested that SIRPG 261 signaling may play an immunoregulatory role in maintaining peripheral immune tolerance and 262 preventing autoimmunity ⁴³. In line with existing studies, our analyses demonstrated that SIRPG 263 expression was enriched in T cells and natural killer cells, where blocking of the SIRPG-CD47 264 interaction has been found to inhibit superantigen-induced T cell proliferation ^{42, 44, 45}. These 265 findings imply the potential significance of investigating SIRPG as a T cell-specific target for type 266 267 1 diabetes, although it should be noted that the genetic instrument for circulating SIRPG abundance was subject to a moderate risk of horizontal pleiotropy due to its associations with 268 269 the expression, splicing, or translation of neighboring genes encoding other signal-regulatory 270 proteins, SIRPB1, SIRPB2, and SIRPD.

271

PGM1 (phosphoglucomutase 1) is an enzyme that catalyzes the reversible conversion between 272 glucose 1-phosphate and glucose 6-phosphate ⁴⁶, which are important intermediates in glucose 273 metabolism. The Mendelian disorders of PGM1 deficiency can result in congenital disorder of 274 glycosylation ⁴⁷. Given the crucial functions of insulin in the uptake of glucose into cells and the 275 regulation of glycogen synthesis and breakdown ⁴⁸, we hypothesize that PGM1 may play a role 276 in type 1 diabetes by affecting the balance between glycogen storage and glucose utilization, 277 278 particularly in muscle and liver tissues. Notably, previous GWASs have suggested that the 279 PGM1-increasing allele of the genetic instrument, which increases the risk of type 1 diabetes, may have a marginal protective effect against type 2 diabetes ^{49, 50}, although this association 280 was not genome-wide significant. Elucidating the precise involvement of PGM1 in diabetes 281 282 mellitus necessitates further efforts.

283

284 Our study has several strengths. First, we harnessed large-scale GWASs to increase the power 285 of MR and colocalization analyses. Specifically, we obtained genetic instruments for circulating protein abundances from a large-scale proteo-genomic study with the highest coverage of the 286 287 circulating proteome to date, and conducted target discovery utilizing the largest meta-analysis 288 of type 1 diabetes GWASs. Notably, the association between circulating SIRPG abundance and 289 the risk of type 1 diabetes was identified in a previous MR study but was not supported by colocalization evidence ¹⁰, which is likely attributable to the smaller sample sizes of GWASs ⁵¹. 290 291 This advantage is also evident when compared to GTEx cis-eQTL-based analyses, which had 292 much smaller sample sizes and failed to demonstrate colocalization evidence in most of the 293 candidate tissues. Second, after cis-pQTL-facilitated MR analyses, we subjected the genetic 294 instruments to rigorous scrutiny, ensuring that the no horizontal pleiotropy assumption was not 295 violated for prioritized proteins. Third, we bolstered the validity of our findings by replicating our results using additional resources. Importantly, analyses using the genetic instruments 296 297 identified in the UKB-PPP study failed to replicate the association between circulating CCL25 298 abundance and type 1 diabetes risk, highlighting the potential influence of protein detection platform and study population. These analyses collectively mitigated the risk of false positive 299 results. Although deprioritized target proteins, such as IL15 RA ^{52, 53} and ERBB3 ^{54, 55}, have been 300

previously linked to the risk of type 1 diabetes in different contexts, substantiating whether these associations truly denote causal effects requires future efforts. Fourth, based upon MRprioritized target proteins, we further identified candidate tissues and cell types where the target protein-coding gene expression was enriched. This characterization yielded valuable insights into the biological relevance, disease mechanisms, as well as the therapeutic potential of these target proteins.

307

308 Our study has important limitations. First of all, our findings have not been experimentally 309 validated, which should be the focus of follow-up studies. Second, our analyses were restricted 310 to populations predominantly of European ancestry. Given the substantial variability in the 311 prevalence and strong heterogeneity of type 1 diabetes across different populations in different countries ³⁻⁵, it is important to exercise caution when generalizing our findings to populations of 312 non-European ancestries. Third, it should be noted that all cis-pQTLs used in this study were 313 314 identified in middle-aged and older adults, whereas the type 1 diabetes GWASs included 315 patients who were more likely to develop the disease at a younger age. However, we posit that 316 the cis-genetic regulation of circulating protein abundances is likely consistent across age 317 distributions. Nevertheless, we strongly advocate for similar analyses to be conducted across 318 populations of diverse ancestries and demographic characteristics. Fourth, although existing 319 protein detection platforms have enabled the measurement of circulating abundances for 320 nearly 5,000 proteins, the possibility remains that potential target proteins lack valid genetic 321 instruments. Genetics-guided target discovery based on proteo-genomic studies featuring 322 increased sample sizes and enhanced coverage of the circulating proteome should be pursued 323 in the future. Last but not least, due to the strong variability and highly intricate LD structure of 324 the MHC region, we did not prioritize MHC gene-coded proteins, despite significant associations 325 identified through MR. Considering the well-established role of the MHC region in the 326 pathogenesis and progression of type 1 diabetes, future efforts should be dedicated to 327 elucidating the functional impacts of these proteins.

328

329 In conclusion, through integrative proteogenomic analyses, we identified significant 330 associations between circulating protein abundances and the risk of type 1 diabetes, which 331 further suggested possible causal effects of CTSH, IL27RA, SIRPG, and PGM1. The roles of CTSH, 332 IL27RA, and SIRPG in the immune system are underscored, with enrichment of CTSH expression 333 in B cells and myeloid cells, and SIRPG expression in T cells and natural killer cells. In contrast, 334 PGM1 may influence the risk of type 1 diabetes through its impact on glucose metabolism, particularly in muscle and liver tissues. Exploration of these target proteins as biomarkers or 335 336 viable candidates for drug targeting strategies while considering the candidate tissues and cell 337 types should be warranted in the context of type 1 diabetes. 338

340 **Online Methods**

341 *Genome-wide association study of circulating protein abundances*

342 Genetic associations with circulating protein abundances were assessed in the Fenland study based on 10,708 unrelated European ancestry individuals ¹². Details of this study have been 343 described previously ^{12, 56}. Abundances of 4,775 proteins and protein complexes from plasma 344 samples were measured using the SomaLogic SomaScan v4 assay, which includes 4,979 distinct 345 346 SOMAmer reagents. GWAS was conducted for each SOMAmer protein target, referred to as "protein" hereinafter. The circulating abundances underwent rank-based inverse normal 347 transformation after regressing out the effects of age, sex, test site, and the first ten genetic 348 principal components ¹². Conditional and joint (COJO) analyses ⁵⁷ were performed to identify 349 conditionally independent lead variants with a p-value $< 1.0 \times 10^{-11}$, which represented the 350 Bonferroni-corrected genome-wide significance threshold. Cis-pQTL variants were defined for 351 352 each protein as conditionally independent lead variants located within 500 kb away from the 353 gene body of the protein-coding gene.

354

355 *Genome-wide association study of type 1 diabetes*

Genetic associations with type 1 diabetes risk were assessed in a meta-analysis of GWASs by Chiou et al. including up to 18,942 patients and 501,638 controls predominantly of European ancestry from nine cohorts ⁵⁸. Details of the participating cohorts and the meta-analysis have been described previously ⁵⁸. There was no known overlap between participants of the Fenland study and participants of this meta-analysis.

361

362 Mendelian randomization and sensitivity analyses

363 Two-sample MR was performed based on GWAS summary statistics to test associations 364 between the genetically predicted circulating abundance of each protein and type 1 diabetes 365 risk. Cis-pQTL variants identified in the Fenland study were used as genetic instruments. Trans-366 genetic variants distal to the protein-coding genes likely act on other genes, thus to mitigate 367 the risk of horizontal pleiotropy, they were not used. If a cis-pQTL variant was unavailable in the type 1 diabetes GWAS summary statistics, we attempted to identify a proxy as the genetic 368 instrument using the LDlink R package ⁵⁹. The proxy should be in high linkage disequilibrium (LD; 369 $r^2 > 0.8$) with the cis-pQTL variant based on the LD reference panel consisting of non-Finnish 370 371 European ancestry populations in the 1000 Genomes Project phase 3⁶⁰. GWAS summary 372 statistics for genetic instruments were harmonized with forward strand alleles inferred using 373 allele frequency information. Palindromic variants with high minor allele frequency (MAF > 0.42) were discarded to avoid allele mismatches. 374

375

Wald ratio estimates were derived for proteins with only one cis-genetic instrument, while inverse variance weighted estimates were derived for proteins with two or more cis-genetic instruments $^{61, 62}$. Associations with a p-value < $3.2x10^{-5}$ were considered significant, representing the Bonferroni-corrected significance threshold to account for 1,565 tests. This significance threshold may be overly conservative due to possible correlation and functional relevance between proteins, but should effectively control the false positive rate.

383 For significant associations where the protein abundances were instrumented using three or more cis-genetic instruments, we conducted sensitivity analyses using the weighted median, 384 penalized weighted median, weighted mode, and MR-Egger methods ⁶¹⁻⁶⁴. An association was 385 considered robust to invalid instruments if these different methods yielded estimates with a 386 387 consistent effect direction and magnitude. A significant MR-Egger intercept (p-value < 0.05) would indicate existence of directional horizontal pleiotropy ⁶⁴. Furthermore, we calculated the 388 F-statistic for each test, where an F-statistic < 10 would indicate a risk of weak instrument bias 389 ⁶⁵. MR analyses were conducted using the TwoSampleMR R package version 0.5.6⁶⁶. 390

391

392 Colocalization analyses

While most genetic instruments are typically not associated with confounders of the exposureoutcome relationship, MR may be confounded by LD, where two genetic variants separately influence the exposure and the outcome through different mechanisms but are correlated with each other through LD ⁶⁷. Colocalization analyses have been widely used to assess whether the exposure and the outcome share the same causal genetic variants, in order to guard against such confounding effects ⁶⁷.

399

For significant associations, we performed colocalization analyses using PWCoCo¹⁶, leveraging 400 GWAS summary statistics of all variants located within 500 kb away from the cis-genetic 401 instruments, and an LD reference panel constructed using 5,000 randomly selected unrelated 402 European ancestry individuals from the UK Biobank ⁶⁸. PWCoCo builds upon the classical 403 algorithm coloc ⁶⁹, but allows for multiple causal variants in the same genomic region through 404 405 an implementation of COJO analyses for the exposure and the outcome separately, and pairwise colocalization analyses of conditionally independent signals ^{16, 57}. We used default 406 407 priors of PWCoCo, i.e. p_1 (prior probability of the exposure having a causal variant) = p_2 (prior probability of the outcome having a causal variant) = 1.0×10^{-4} , and p_{12} (prior probability of the 408 exposure and the outcome sharing the same causal variant) = 1.0×10^{-5} . A colocalization 409 410 probability (PP.H4) > 80% was considered strong evidence of colocalization, while a PP.H4 > 50% 411 was considered suggestive evidence of colocalization. We excluded proteins whose coding 412 genes map to the major histocompatibility complex (MHC) region due to the strong variability 413 and highly intricate LD structure.

414

415 Annotation of genetic instruments and phenome-wide association study

To further evaluate potential horizontal pleiotropic effects, we obtained variant-to-gene (V2G) annotations ⁷⁰ and phenome-wide associations from publicly available GWASs in Open Targets ^{71, 72} (retrieved July 1, 2023) for each genetic instrument. Specifically, the V2G scores were derived from a machine learning model trained to distinguish true causal genes from neighboring genes in the same genomic region ⁷⁰. Therefore, the V2G scores can be a quantitative measure of the functional connection between a variant and a gene.

422

423 We considered a genetic instrument to be subject to a high risk of horizontal pleiotropy if the 424 gene with the highest V2G score paired with this variant was not the target protein-coding gene.

- 425 Furthermore, a genetic variant was considered to be subject to a moderate risk of horizontal
- 426 pleiotropy if it had been associated with the expression, splicing, or translation of one or more

genes in proximity other than the target protein-coding gene. Additionally, variants
demonstrating associations with other established risk factors of type 1 diabetes were also
considered to have a moderate risk of horizontal pleiotropy.

430

431 *Replication of findings*

432 Significant associations that were supported by strong or suggestive colocalization evidence were replicated in two ways. First, we repeated MR analyses for these proteins using cis-genetic 433 instruments identified in the deCODE study ¹³ and the UK Biobank Pharma Proteomics Project 434 (UKB-PPP) study ⁷³. The deCODE study measured circulating plasma abundances of 4,907 435 SOMAmer protein targets in 35,559 individuals from Iceland, employing the same SomaLogic 436 SomaScan v4 assay as in the Fenland study ¹³. However, the genetic architecture underlying 437 circulating protein abundances and LD structures in the Icelandic population may differ from 438 those in other European ancestry populations due to extensive genetic drift ⁷⁴. On the other 439 hand, the UKB-PPP study measured plasma circulating abundances of 2,923 protein analytes 440 using the Olink Explore 1536 platform ⁷³. The discovery of pQTLs were conducted based on 441 35,571 European ancestry individuals. This cohort overlapped with participants in the meta-442 analysis of type 1 diabetes GWASs by Chiou et al ⁵⁸. 443

444

454

Second, we repeated MR analyses for these proteins leveraging a different meta-analysis of 445 type 1 diabetes GWASs by Robertson et al.⁷⁵, using cis-genetic instruments identified in the 446 Fenland study. This meta-analysis comprised up to 16,159 patients, 25,386 controls, and 6,143 447 448 trio families with an affected offspring and both parents, including 7,117 participants of non-European (African, East Asian, or admixed) ancestries ⁷⁵. Although participants in this meta-449 analysis partially overlapped with those in the primary analysis by Chiou et al. ⁵⁸, genotyping in 450 this study by Robertson et al. was conducted using the Illumina ImmunoChip, which provided 451 452 dense coverage in 188 immune-relevant genomic regions, but sparse coverage in other regions 75 453

455 **Quantification of tissue-specific gene expression**

We investigated the tissue specificity of prioritized proteins leveraging gene expression profiles 456 from the Genotype-Tissue Expression (GTEx) project version 8⁷⁶. Following previous studies⁷⁷, 457 458 ⁷⁸, we quantified the enrichment of gene expression in each of the 54 non-diseased tissue sites 459 across approximately 1,000 individuals. Specifically, we first retained genes that were detected 460 in at least 20% of the samples with at least 5 read counts. We performed per-tissue trimmed mean of M-values (TMM) normalization using the edgeR R package ⁷⁹. Then, we calculated the 461 median TMM value across individuals for each gene in each tissue. Subsequently, within each 462 463 tissue, we standardized the across-individual median TMM values, using the median and the median absolute deviation across genes. Finally, for each gene, the tissue-specific enrichment z-464 scores were calculated by standardizing the within-tissue standardized across-individual median 465 466 TMM values, using the median and the median absolute deviation across tissues. Tissues with 467 an enrichment z-score > 10 were considered to be enriched of expression of the corresponding 468 gene.

469

470 Genetic effects on tissue-specific gene expression

471 Next, in each tissue that demonstrated enrichment of gene expression, we tested colocalization
472 of the genetic associations with gene expression and splicing patterns and the risk of type 1
473 diabetes for each target protein-coding gene. Genetic associations with mRNA abundances and
474 isoform abundances were obtained respectively from the cis-expression and cis-splicing
475 quantitative trait loci (eQTL and sQTL) analyses conducted by the GTEx Consortium ⁷⁶.
476 Colocalization analyses were performed using PWCoCo with default priors as described above ¹⁶.
477

- 478 Single-cell gene expression profiling
- 479 Since tissues that play a significant role in the immune system were implicated, we further investigated whether target protein-coding genes were enriched in specific immune cell types. 480 481 We obtained single-cell gene expression profiles from a cross-tissue analysis that included highquality 329,762 immune cells from 12 donors ⁸⁰. Details of this study, including sample 482 collection, single-cell RNA sequencing and paired VDJ sequencing for T cell and B cell receptors, 483 and data processing, have been described previously ⁸⁰. In this study, manual curation was 484 485 conducted after automated annotation, using existing cell type-specific gene expression 486 signatures to identify 45 cell types. These cell types were classified as: B cell compartment, T cell compartment (predominantly T cells and natural killer cells), and myeloid compartment 487 (predominantly macrophages, monocytes, and dendritic cells)⁸⁰. We evaluated the normalized 488 gene expression level of each target protein-coding gene in each cell and compared the 489 490 distribution of gene expression levels between different cell types.
- 491

492 Clinically relevant variants affecting target protein-coding genes

To assess whether the prioritized proteins may be associated with other human diseases, we queried the ClinVar database (June 9th, 2023)⁸¹ to identify Mendelian disorders that are caused by variants affecting the target protein-coding genes. Mendelian disorder-causing variants must be pathogenic or likely pathogenic variants with at least one submitter providing assertion criteria, which should not have conflicting interpretations.

498

499 **Observational associations with incident disease outcomes in the UK Biobank**

500 Finally, we obtained observational association test statistics from a recent study to evaluate 501 whether measured circulating protein abundances could predict future disease outcomes in the 502 UK Biobank over 16 years of follow-up ⁸². The associations between each protein and mortality 503 and 23 incident morbidities were estimated using Cox proportional hazards models, based on 504 49,234 individuals predominantly of European ancestry, adjusted for the fixed effects of age 505 and sex, or for age only in the case of sex-specific diseases ⁸². 506

507 Acknowledgements

508 T.L. has been supported by a Schmidt AI in Science Postdoctoral Fellowship. The funder has no 509 role in study design; collection, management, analysis and interpretation of data; or the 510 decision to submit for publication.

511

512 *Conflicts of interest*

513 T.L. was employed by 5 Prime Sciences Inc. until Sept 2023. The research presented in this

paper was conducted independently, and 5 Prime Sciences Inc. was not involved in the design,
 execution, analysis, or interpretation of the study. T.L. declares no ongoing conflicts of interest.

- 516 The other authors declare no conflicts of interest.
- 517

518 Data availability

519 All results generated in this study are included in Supplementary Tables.

521 References

Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. *Diabetes*.
 Oct 1965;14(10):619-33. doi:10.2337/diab.14.10.619

524 2. Eisenbarth GS. Type | diabetes mellitus. A chronic autoimmune disease. N Engl J Med.
525 May 22 1986;314(21):1360-8. doi:10.1056/NEJM198605223142106

526 3. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. *The Lancet*. 527 2014;383(9911):69-82.

528 4. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. *The Lancet*. 529 2018;391(10138):2449-2462.

530 5. Katsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. *Nature* 531 *reviews Disease primers*. 2017;3(1):1-17.

532 6. Daneman D. Type 1 diabetes. *The Lancet*. 2006;367(9513):847-858.

533 7. Oram RA, Patel K, Hill A, et al. A Type 1 Diabetes Genetic Risk Score Can Aid 534 Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. *Diabetes Care*. Mar 535 2016;39(3):337-44. doi:10.2337/dc15-1111

Redondo MJ, Geyer S, Steck AK, et al. A Type 1 Diabetes Genetic Risk Score Predicts
 Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk.
 Diabetes Care. Sep 2018;41(9):1887-1894. doi:10.2337/dc18-0087

539 9. Sharp SA, Rich SS, Wood AR, et al. Development and standardization of an improved
540 type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis. *Diabetes*541 *care*. 2019;42(2):200-207.

542 10. Yazdanpanah N, Yazdanpanah M, Wang Y, et al. Clinically Relevant Circulating Protein
543 Biomarkers for Type 1 Diabetes: Evidence From a Two-Sample Mendelian Randomization Study.
544 Diabetes Care. Jan 1 2022;45(1):169-177. doi:10.2337/dc21-1049

545 11. Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome.
546 *Nature*. Jun 2018;558(7708):73-79. doi:10.1038/s41586-018-0175-2

547 12. Pietzner M, Wheeler E, Carrasco-Zanini J, et al. Mapping the proteo-genomic 548 convergence of human diseases. *Science*. Oct 14 2021:eabj1541. doi:10.1126/science.abj1541

549 13. Ferkingstad E, Sulem P, Atlason BA, et al. Large-scale integration of the plasma
550 proteome with genetics and disease. *Nat Genet*. Dec 2021;53(12):1712-1721.
551 doi:10.1038/s41588-021-00978-w

552 14. Chen Y, Lu T, Pettersson-Kymmer U, et al. Genomic atlas of the plasma metabolome
553 prioritizes metabolites implicated in human diseases. *Nat Genet*. Jan 2023;55(1):44-53.
554 doi:10.1038/s41588-022-01270-1

Long AE, Gillespie KM, Rokni S, Bingley PJ, Williams AJ. Rising incidence of type 1
diabetes is associated with altered immunophenotype at diagnosis. *Diabetes*. 2012;61(3):683686.

558 16. Zheng J, Haberland V, Baird D, et al. Phenome-wide Mendelian randomization mapping
559 the influence of the plasma proteome on complex diseases. *Nature genetics*. 2020;52(10):1122560 1131.

561 17. Skrivankova VW, Richmond RC, Woolf BA, et al. Strengthening the reporting of 562 observational studies in epidemiology using mendelian randomisation (STROBE-MR): 563 explanation and elaboration. *bmj*. 2021;375

564 18. Skrivankova VW, Richmond RC, Woolf BA, et al. Strengthening the Reporting of
565 Observational Studies in Epidemiology using Mendelian Randomization: the STROBE-MR
566 Statement. JAMA. 2021;326(16):1614-1621.

Yao C, Chen G, Song C, et al. Genome-wide mapping of plasma protein QTLs identifies
putatively causal genes and pathways for cardiovascular disease. *Nat Commun.* Aug 15
2018;9(1):3268. doi:10.1038/s41467-018-05512-x

570 20. Chong M, Sjaarda J, Pigeyre M, et al. Novel Drug Targets for Ischemic Stroke Identified 571 Through Mendelian Randomization Analysis of the Blood Proteome. *Circulation*. Sep 9 572 2019;140(10):819-830. doi:10.1161/CIRCULATIONAHA.119.040180

Lu T, Forgetta V, Greenwood CMT, Zhou S, Richards JB. Circulating Proteins Influencing
Psychiatric Disease: A Mendelian Randomization Study. *Biol Psychiatry*. Jan 1 2023;93(1):82-91.
doi:10.1016/j.biopsych.2022.08.015

576 22. Yoshiji S, Butler-Laporte G, Lu T, et al. Proteome-wide Mendelian randomization
577 implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity.
578 Nature Metabolism. 2023;5(2):248-264.

579 23. Beck RW, Bergenstal RM, Laffel LM, Pickup JC. Advances in technology for management 580 of type 1 diabetes. *Lancet*. Oct 5 2019;394(10205):1265-1273. doi:10.1016/S0140-581 6736(19)31142-0

582 24. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type
583 1 diabetes. *N Engl J Med*. Nov 20 2014;371(21):1972-82. doi:10.1056/NEJMoa1408214

584 25. Conus S, Simon HU. Cathepsins: key modulators of cell death and inflammatory 585 responses. *Biochem Pharmacol*. Dec 1 2008;76(11):1374-82. doi:10.1016/j.bcp.2008.07.041

58626.Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and587disease. J Clin Invest. Oct 2010;120(10):3421-31. doi:10.1172/JCI42918

588 27. Floyel T, Brorsson C, Nielsen LB, et al. CTSH regulates beta-cell function and disease 589 progression in newly diagnosed type 1 diabetes patients. *Proc Natl Acad Sci U S A*. Jul 15 590 2014;111(28):10305-10. doi:10.1073/pnas.1402571111

591 28. D'Angelo ME, Bird PI, Peters C, Reinheckel T, Trapani JA, Sutton VR. Cathepsin H is an 592 additional convertase of pro-granzyme B. *Journal of Biological Chemistry*. 2010;285(27):20514-593 20519.

29. Cooper JD, Smyth DJ, Smiles AM, et al. Meta-analysis of genome-wide association study
data identifies additional type 1 diabetes risk loci. *Nat Genet*. Dec 2008;40(12):1399-401.
doi:10.1038/ng.249

30. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and metaanalysis find that over 40 loci affect risk of type 1 diabetes. *Nature genetics*. 2009;41(6):703-707.
31. Ye J, Richardson TG, McArdle WL, et al. Identification of loci where DNA methylation potentially mediates genetic risk of type 1 diabetes. *J Autoimmun*. Sep 2018;93:66-75.
doi:10.1016/j.jaut.2018.06.005

602 32. Usher-Smith JA, Thompson MJ, Sharp SJ, Walter FM. Factors associated with the 603 presence of diabetic ketoacidosis at diagnosis of diabetes in children and young adults: a 604 systematic review. *Bmj*. 2011;343

60533.Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT. Frequency and606phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically

stratified survival analysis from UK Biobank. *Lancet Diabetes Endocrinol*. Feb 2018;6(2):122-129.
doi:10.1016/S2213-8587(17)30362-5

Mortensen HB, Swift PG, Holl RW, et al. Multinational study in children and adolescents
with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and
autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. *Pediatr Diabetes*. Jun 2010;11(4):218-26. doi:10.1111/j.1399-5448.2009.00566.x

613 35. Inshaw JR, Cutler AJ, Crouch DJ, Wicker LS, Todd JA. Genetic variants predisposing most
614 strongly to type 1 diabetes diagnosed under age 7 years lie near candidate genes that function
615 in the immune system and in pancreatic β-cells. *Diabetes Care*. 2020;43(1):169-177.

616 36. Yoshida H, Hunter CA. The immunobiology of interleukin-27. *Annu Rev Immunol*. 617 2015;33:417-43. doi:10.1146/annurev-immunol-032414-112134

618 37. Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3
619 and p28 protein, induces proliferation of naive CD4+ T cells. *Immunity*. Jun 2002;16(6):779-90.
620 doi:10.1016/s1074-7613(02)00324-2

621 38. Owaki T, Asakawa M, Fukai F, Mizuguchi J, Yoshimoto T. IL-27 induces Th1
622 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2623 dependent pathways. J Immunol. Dec 1 2006;177(11):7579-87.
624 doi:10.4049/jimmunol.177.11.7579

625 39. Artis D, Villarino A, Silverman M, et al. The IL-27 receptor (WSX-1) is an inhibitor of 626 innate and adaptive elements of type 2 immunity. *The Journal of Immunology*. 627 2004;173(9):5626-5634.

40. Stumhofer JS, Laurence A, Wilson EH, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. *Nat Immunol*. Sep 2006;7(9):937-45. doi:10.1038/ni1376

631 41. Stumhofer JS, Tait ED, lii WJQ, et al. A role for IL-27p28 as an antagonist of gp130-632 mediated signaling. *Nature immunology*. 2010;11(12):1119-1126.

Brooke G, Holbrook JD, Brown MH, Barclay AN. Human lymphocytes interact directly
with CD47 through a novel member of the signal regulatory protein (SIRP) family. *The Journal of Immunology*. 2004;173(4):2562-2570.

636 43. Sharp RC, Brown ME, Shapiro MR, Posgai AL, Brusko TM. The Immunoregulatory Role of
637 the Signal Regulatory Protein Family and CD47 Signaling Pathway in Type 1 Diabetes. *Front*638 *Immunol.* 2021;12:739048. doi:10.3389/fimmu.2021.739048

44. Hatherley D, Graham SC, Turner J, Harlos K, Stuart DI, Barclay AN. Paired receptor
specificity explained by structures of signal regulatory proteins alone and complexed with CD47. *Molecular cell*. 2008;31(2):266-277.

642 45. Dehmani S, Nerriere-Daguin V, Neel M, et al. SIRPgamma-CD47 Interaction Positively
643 Regulates the Activation of Human T Cells in Situation of Chronic Stimulation. *Front Immunol*.
644 2021;12:732530. doi:10.3389/fimmu.2021.732530

46. Quick CB, Fisher RA, Harris H. A kinetic study of the isozymes determined by the three
human phosphoglucomutase loci PGM1, PGM2, and PGM3. *Eur J Biochem*. Mar 1
1974;42(2):511-7. doi:10.1111/j.1432-1033.1974.tb03366.x

648 47. Tegtmeyer LC, Rust S, van Scherpenzeel M, et al. Multiple phenotypes in
649 phosphoglucomutase 1 deficiency. *N Engl J Med*. Feb 6 2014;370(6):533-42.
650 doi:10.1056/NEJMoa1206605

48. Wilcox G. Insulin and insulin resistance. *Clinical biochemist reviews*. 2005;26(2):19.

49. Inshaw JRJ, Sidore C, Cucca F, et al. Analysis of overlapping genetic association in type 1

and type 2 diabetes. *Diabetologia*. Jun 2021;64(6):1342-1347. doi:10.1007/s00125-021-05428-0

50. Xue A, Wu Y, Zhu Z, et al. Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. *Nat Commun*. Jul 27 2018;9(1):2941. doi:10.1038/s41467-018-04951-w

57 51. Forgetta V, Manousaki D, Istomine R, et al. Rare Genetic Variants of Large Effect 58 Influence Risk of Type 1 Diabetes. *Diabetes*. Apr 2020;69(4):784-795. doi:10.2337/db19-0831

52. Bobbala D, Mayhue M, Menendez A, Ilangumaran S, Ramanathan S. Trans-presentation of interleukin-15 by interleukin-15 receptor alpha is dispensable for the pathogenesis of autoimmune type 1 diabetes. *Cellular & molecular immunology*. 2017;14(7):590-596.

Kuczyński S, Winiarska H, Abramczyk M, Szczawińska K, Wierusz-Wysocka B, Dworacka
M. IL-15 is elevated in serum patients with type 1 diabetes mellitus. *Diabetes research and clinical practice*. 2005;69(3):231-236.

Kaur S, Mirza AH, Brorsson CA, et al. The genetic and regulatory architecture of ERBB3type 1 diabetes susceptibility locus. *Mol Cell Endocrinol*. Jan 5 2016;419:83-91.
doi:10.1016/j.mce.2015.10.002

55. Wang H, Jin Y, Reddy MV, et al. Genetically dependent ERBB3 expression modulates
antigen presenting cell function and type 1 diabetes risk. *PLoS One*. Jul 26 2010;5(7):e11789.
doi:10.1371/journal.pone.0011789

671 56. O'Connor L, Brage S, Griffin SJ, Wareham NJ, Forouhi NG. The cross-sectional association
672 between snacking behaviour and measures of adiposity: the Fenland Study, UK. *British journal*673 of nutrition. 2015;114(8):1286-1293.

57. Yang J, Ferreira T, Morris AP, et al. Conditional and joint multiple-SNP analysis of GWAS
summary statistics identifies additional variants influencing complex traits. *Nat Genet*. Mar 18
2012;44(4):369-75, S1-3. doi:10.1038/ng.2213

57 58. Chiou J, Geusz RJ, Okino M-L, et al. Interpreting type 1 diabetes risk with genetics and single-cell epigenomics. *Nature*. 2021;594(7863):398-402.

59. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring populationspecific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics*. Nov 1 2015;31(21):3555-7. doi:10.1093/bioinformatics/btv402

682 60. Genomes Project C, Auton A, Brooks LD, et al. A global reference for human genetic 683 variation. *Nature*. Oct 1 2015;526(7571):68-74. doi:10.1038/nature15393

684 61. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for 685 Mendelian randomization. *Stat Methods Med Res.* Oct 2017;26(5):2333-2355. 686 doi:10.1177/0962280215597579

687 62. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A 688 framework for the investigation of pleiotropy in two-sample summary data Mendelian 689 randomization. *Stat Med*. May 20 2017;36(11):1783-1802. doi:10.1002/sim.7221

690 63. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian 691 randomization with some invalid instruments using a weighted median estimator. *Genetic* 692 *epidemiology*. 2016;40(4):304-314.

693 64. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: 694 effect estimation and bias detection through Egger regression. *International journal of* 695 *epidemiology*. 2015;44(2):512-525.

696 65. Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in 697 Mendelian randomization studies. *Int J Epidemiol*. Jun 2011;40(3):755-64. 698 doi:10.1093/ije/dyr036

699 66. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal 700 inference across the human phenome. *Elife*. May 30 2018;7doi:10.7554/eLife.34408

701 67. Zuber V, Grinberg NF, Gill D, et al. Combining evidence from Mendelian randomization
702 and colocalization: Review and comparison of approaches. *Am J Hum Genet*. May 5
703 2022;109(5):767-782. doi:10.1016/j.ajhg.2022.04.001

70468.Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping705and genomic data. Nature. Oct 2018;562(7726):203-209. doi:10.1038/s41586-018-0579-z

Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation between
pairs of genetic association studies using summary statistics. *PLoS Genet*. May
2014;10(5):e1004383. doi:10.1371/journal.pgen.1004383

709 70. Mountjoy E, Schmidt EM, Carmona M, et al. An open approach to systematically 710 prioritize causal variants and genes at all published human GWAS trait-associated loci. *Nature* 711 *genetics*. 2021;53(11):1527-1533.

71. Ghoussaini M, Mountjoy E, Carmona M, et al. Open Targets Genetics: systematic
713 identification of trait-associated genes using large-scale genetics and functional genomics.
714 *Nucleic Acids Res.* Jan 8 2021;49(D1):D1311-D1320. doi:10.1093/nar/gkaa840

715 72. Ochoa D, Hercules A, Carmona M, et al. Open Targets Platform: supporting systematic
716 drug-target identification and prioritisation. *Nucleic Acids Res.* Jan 8 2021;49(D1):D1302-D1310.
717 doi:10.1093/nar/gkaa1027

718 73. Sun BB, Chiou J, Traylor M, et al. Plasma proteomic associations with genetics and 719 health in the UK Biobank. *Nature*. Oct 2023;622(7982):329-338. doi:10.1038/s41586-023-720 06592-6

74. Ebenesersdottir SS, Sandoval-Velasco M, Gunnarsdottir ED, et al. Ancient genomes from
lceland reveal the making of a human population. *Science*. Jun 1 2018;360(6392):1028-1032.
doi:10.1126/science.aar2625

724 75. Robertson CC, Inshaw JRJ, Onengut-Gumuscu S, et al. Fine-mapping, trans-ancestral and
725 genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. *Nat*726 *Genet*. Jul 2021;53(7):962-971. doi:10.1038/s41588-021-00880-5

727 76. Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across human
728 tissues. *Science*. Sep 11 2020;369(6509):1318-1330. doi:10.1126/science.aaz1776

729 77. Verweij N, Haas ME, Nielsen JB, et al. Germline Mutations in CIDEB and Protection 730 against Liver Disease. *N Engl J Med*. Jul 28 2022;387(4):332-344. doi:10.1056/NEJMoa2117872

731 78. Akbari P, Gilani A, Sosina O, et al. Sequencing of 640,000 exomes identifies GPR75
732 variants associated with protection from obesity. *Science*. Jul 2
733 2021;373(6550)doi:10.1126/science.abf8683

734 79. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential 735 expression analysis of digital gene expression data. *Bioinformatics*. Jan 1 2010;26(1):139-40.

736 doi:10.1093/bioinformatics/btp616

737 80. Dominguez Conde C, Xu C, Jarvis LB, et al. Cross-tissue immune cell analysis reveals
738 tissue-specific features in humans. *Science*. May 13 2022;376(6594):eabl5197.
739 doi:10.1126/science.abl5197

740 81. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among 741 sequence variation and human phenotype. *Nucleic acids research*. 2014;42(D1):D980-D985.

742 82. Gadd DA, Hillary RF, Kuncheva Z, et al. Blood protein levels predict leading incident

diseases and mortality in UK Biobank. *medRxiv*. 2023:2023.05. 01.23288879.



Figure 1. Overview of study. Mendelian randomization (MR) was conducted leveraging genome-wide association studies (GWASs) of circulating protein abundances in the Fenland study as well as a meta-analysis of type 1 diabetes GWASs. Colocalization analyses and evaluation of horizontal pleiotropy through annotation and phenome-wide association study (PheWAS) were conducted to verify MR assumptions. Significant associations were replicated using other proteomic studies and another meta-analysis of type 1 diabetes GWASs. Gene expression enrichment analyses were conducted to identify potential candidate tissues and cell types.



Figure 2. Target protein prioritization. Associations between circulating protein abundances and type 1 diabetes risk that withstood Bonferroni correction of multiple testing are illustrated. Target proteins are ordered by posterior probability of colocalization (Supplementary Table S4). A posterior probability of colocalization > 80% was considered strong evidence of colocalization, while a posterior probability of colocalization > 50% was considered suggestive evidence of colocalization. Risk of horizontal pleiotropy was assessed using V2G scores for quantifying functional connections between genetic instruments and target protein-coding genes, as well as phenome-wide associations for exploring potential pleiotropic pathways (Methods). Associations supported by strong or suggestive colocalization evidence were replicated using additional resources (Methods). Blank space indicates that no genetic instrument or proxy was identified to replicate the association. Target proteins were prioritized based on strong or suggestive colocalization evidence, the absence of a high risk of horizontal pleiotropy, and the consistent replication of associations with the risk of type 1 diabetes.



Figure 3. Colocalization of genetic associations with circulating abundances of prioritized target proteins and the risk of type 1 diabetes. The lead cis-genetic instruments are indicated. Genetic variants located in a ±500kb window centered around each genetic instrument are plotted with their significance in respective studies, and colored by the magnitude of correlation (linkage disequilibrium, LD r2) with the corresponding instrument. For each target protein, the posterior probability of colocalization (PP.H4) and the posterior probability of co-existence of two distinct causal variants (PP.H3) are indicated. The UCSC known gene tracks are presented, with gene models colored by their respective strands.



Figure 4. Quantification of tissue-specific gene expression. Gene expression profiles were obtained from the Genotype-Tissue Expression (GTEx) project version 8 across 54 tissue sites. Gene expression levels were normalized to account for between- and within-sample variation (Methods). For each gene, the enrichment z-scores represent standardized median gene expression levels across all tissues. Red dashed line indicates an arbitrary threshold, z-score > 10, for determining significance of enrichment.



Figure 5. Single-cell gene expression profiles of *CTSH*, *IL27RA*, and *SIRPG* in immune cells. (A) Visualization of 329,762 immune cells based on Uniform Manifold Approximation and Projection (UMAP) of their transcriptomes. Cells are colored by manually curated cell types. Red colors: B cell compartment; Green colors: myeloid compartment; Purple colors: miscellaneous cell types; Blue colors: T cell compartment. Descriptions of cell types are available in Supplementary Table S11. Normalized gene expression levels of (B) *CTSH*, (C) *IL27RA*, and (D) *SIRPG* are visualized. UMAP coordinates, cell type annotations, and normalized gene expression levels were obtained from the Single Cell Portal (https://singlecell.broadinstitute.org/single_cell) under the accession ID SCP1845.